Search research articles
Contact Us
Filters
Showing results (21-30 of 30) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 30 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 29, 2019
Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors
M D Hellmann, T-W Kim, C B Lee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 22, 2022
Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis
H Borghaei, T-E Ciuleanu, J-S Lee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 5, 2021
IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies
D M Barrios, G S Phillips, A N Geisler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 31, 2018
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers
J K Sabari, G C Leonardi, C A Shu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 19, 2020
Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50
J F Gainor, H Rizvi, E Jimenez Aguilar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 16, 2019
EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
K Hastings, H A Yu, W Wei, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 21, 2020
COVID-19 in patients with lung cancer
J Luo, H Rizvi, I R Preeshagul, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 9, 2018
Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)
T R Cottrell, E D Thompson, P M Forde, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 9, 2023
Erratum to "Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project": [Annals of Oncology 32 (2021) 1626-1636]
D M Vega, L M Yee, L M McShane, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 4, 2021
Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project
D M Vega, L M Yee, L M McShane, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 30) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 30 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 29, 2019
Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors
M D Hellmann, T-W Kim, C B Lee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 22, 2022
Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis
H Borghaei, T-E Ciuleanu, J-S Lee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 5, 2021
IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies
D M Barrios, G S Phillips, A N Geisler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 31, 2018
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers
J K Sabari, G C Leonardi, C A Shu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 19, 2020
Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50
J F Gainor, H Rizvi, E Jimenez Aguilar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 16, 2019
EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
K Hastings, H A Yu, W Wei, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 21, 2020
COVID-19 in patients with lung cancer
J Luo, H Rizvi, I R Preeshagul, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 9, 2018
Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)
T R Cottrell, E D Thompson, P M Forde, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 9, 2023
Erratum to "Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project": [Annals of Oncology 32 (2021) 1626-1636]
D M Vega, L M Yee, L M McShane, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 4, 2021
Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project
D M Vega, L M Yee, L M McShane, et al.
Page
of 3